Although the benefits of vertical sleeve
gastrectomy surgery (VSG) are well known, the molecular mechanisms by which VSG alleviates
obesity and its complications remain unclear. We aim to determine a role of
CYP8B1 (
cytochrome P450, family 8, subfamily B,
polypeptide 1) in mediating the metabolic benefits of VSG.
APPROACH RESULTS: We found that expression of
CYP8B1, a key
enzyme in controlling the 12α-hydroxylated (12α-OH)
bile acid (BA) to non-12α-OH BA ratio, was strongly downregulated after VSG. Using genetic mouse models of
CYP8B1 overexpression, knockdown, and knockout (KO), we demonstrated that overexpression of
CYP8B1 dampened the metabolic improvements associated with VSG. In contrast,
shRNA mediated
CYP8B1 knockdown improved metabolism similar to those observed after VSG.
Cyp8b1 deficiency diminished the metabolic effects of VSG. Further, VSG-induced alterations to the 12α-
OH/non-12α-
OH BA ratio in the BA pool depended on
CYP8B1 expression level. Consequently, intestinal
lipid absorption was restricted, and the gut microbiota (GM) profile was altered.
Fecal microbiota transplantation (FMT) from wild type (WT)-VSG mice (vs. FMT from WT-
sham mice) improved metabolism in recipient mice, while there were no differences between mice that received FMT from KO-
sham and KO-VSG mice.
CONCLUSIONS:
CYP8B1 is a critical downstream target of VSG. Modulation of BA composition and GM profile by targeting
CYP8B1 may provide novel insight into the development of
therapies that non-invasively mimic
bariatric surgery to treat
obesity and its complications.